J Intern Med:与IgA肾病相关的罕见变异研究

2016-11-12 MedSci MedSci原创

IgA肾病(IgAN)是一种常见的复杂疾病,与遗传相关。我们的目的是,通过全基因组测序(WES)进行家系连锁分析,识别新的、罕见的、与之高度相关的风险变异。 对16个南意大利血统进行了家系连锁分析。8例信息丰富的案例和2例家庭案例,以及家庭内部对照组,进行WES。通过Sanger测序识别和验证相关区域的高优先级的风险变异。对16个家系、240例IgA肾病患者和113名健康对照者(独立队列)进

IgA肾病(IgAN)是一种常见的复杂疾病,与遗传相关。目的是,通过全基因组测序(WES)进行家系连锁分析,识别新的、罕见的、与之高度相关的风险变异。

对16个南意大利血统进行了家系连锁分析。8例信息丰富的案例和2例家庭案例,以及家庭内部对照组,进行WES。通过Sanger测序识别和验证相关区域的高优先级的风险变异。对16个家系、240例IgA肾病患者和113名健康对照者(独立队列)进行了自定义的TaqMan分析。

发现12个位点可能存在连锁信号。后序贯滤波和WES数据验证后,确定了24个极为罕见(MAF <0.0003)与IgAN相关的变异。这些都是存在于23个基因的编码或调节区域,合并成一个共同的功能网络。这些基因通过AKT、CTNNB、NFKB、MYC、UBCWnt/β-连环蛋白和PI3K/Akt信号通路的关键分子进行连接,暗示了IgAN的可能发病机制。这些功能网络中包含了糖皮质激素受体基因,NR3C1,也是糖皮质激素治疗IgAN时的目标。

研究结果表明,可能是共同功能网络中的多个罕见变异,导致了疾病的易感性,识别这些潜在药物靶点,可以为患者提供个性化治疗。

原始出处:

S. N. Cox, F. Pesce, J.S. El-Sayed Moustafa, F. Sallustio, G. Serino, C. Kkoufou, A. Giampetruzzi, N. Ancona, M. Falchi, F. P. Schena and on behalf of the European IgAN ConsortiumMultiple rare genetic variants co-segregating with familial IgA nephropathy all act within a single immune-related network.J Intern Med.11 OCT 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636059, encodeId=fbe7163605978, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Sun Oct 22 05:22:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342363, encodeId=dc5e134236343, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414595, encodeId=ab9d141459539, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467167, encodeId=4fd7146e16778, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503892, encodeId=b89c1503892da, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607192, encodeId=6cda160e192e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636059, encodeId=fbe7163605978, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Sun Oct 22 05:22:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342363, encodeId=dc5e134236343, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414595, encodeId=ab9d141459539, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467167, encodeId=4fd7146e16778, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503892, encodeId=b89c1503892da, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607192, encodeId=6cda160e192e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636059, encodeId=fbe7163605978, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Sun Oct 22 05:22:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342363, encodeId=dc5e134236343, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414595, encodeId=ab9d141459539, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467167, encodeId=4fd7146e16778, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503892, encodeId=b89c1503892da, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607192, encodeId=6cda160e192e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636059, encodeId=fbe7163605978, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Sun Oct 22 05:22:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342363, encodeId=dc5e134236343, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414595, encodeId=ab9d141459539, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467167, encodeId=4fd7146e16778, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503892, encodeId=b89c1503892da, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607192, encodeId=6cda160e192e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-14 syscxl
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636059, encodeId=fbe7163605978, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Sun Oct 22 05:22:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342363, encodeId=dc5e134236343, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414595, encodeId=ab9d141459539, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467167, encodeId=4fd7146e16778, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503892, encodeId=b89c1503892da, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607192, encodeId=6cda160e192e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-14 yibei
  6. [GetPortalCommentsPageByObjectIdResponse(id=1636059, encodeId=fbe7163605978, content=<a href='/topic/show?id=7af1e9545b1' target=_blank style='color:#2F92EE;'>#罕见变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79545, encryptionId=7af1e9545b1, topicName=罕见变异)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17f122575821, createdName=夏天与十三菇凉, createdTime=Sun Oct 22 05:22:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342363, encodeId=dc5e134236343, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1414595, encodeId=ab9d141459539, content=<a href='/topic/show?id=c83e94827d' target=_blank style='color:#2F92EE;'>#IgA肾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9482, encryptionId=c83e94827d, topicName=IgA肾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7c3073380, createdName=huiwelcome, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467167, encodeId=4fd7146e16778, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503892, encodeId=b89c1503892da, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607192, encodeId=6cda160e192e7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Nov 14 08:22:00 CST 2016, time=2016-11-14, status=1, ipAttribution=)]

相关资讯

CJASN:控制尿蛋白和血压是防止IgA肾病进展的关键

北京大学第一医院肾内科吕继成教授等开展的一项前瞻性研究表明,对于我国IgA肾病患者,有效控制尿蛋白和血压是预防估算肾小球滤过率(eGFR)下降和终末期肾病的关键措施。 研究者指出,目前IgA肾病的治疗措施主要包括肾素-血管紧张素系统阻滞剂和激素。在该研究中,703例IgA肾病患者至少接受 12 个月随访,平均随访 45个月。受试者的eGFR年下降速度为3.12 m

Kidney Int:亚太裔IgA肾病患者更易发生ESRD

加拿大一项研究表明,与其他族裔IgA肾病患者相比,亚太裔患者进展至终末期肾脏病(ESRD)的风险升高。 研究分别纳入202例自报为亚太裔的IgA肾病患者以及467例其他族裔患者。发展至ESRD是指需要透析、移植或估计的肾小球滤过率(eGFR)<15 ml/(min/1.73m2)。 结果显示,受试者的基线eGFR为59.6 ml/(min/1.73m2),中位蛋

ERA-EDTA 2016:糖皮质激素治疗可减少肾衰竭也明显增加严重不良事件

北京大学第一医院肾脏内科张宏教授代表TESTING研究(评价糖皮质激素治疗IgA肾病全球研究)协作组,近日在维也纳召开的2016年欧洲肾脏病年会上报告了该研究的中期分析结果。研究显示:对于全球最常见的肾小球肾炎--IgA肾病,糖皮质激素(甲基强的松龙)治疗虽然可以减少三分之二以上的肾衰竭事件,但是也明显增加患者包括致死性感染在内的严重不良事件。这一重要发现作为本届欧洲肾脏病大会的“重大临床试验结果

中医“从咽论治”联合西药治疗IgA肾病的临床研究

近日,南京医科大学第二附属医院肾内科研究人员发表论文,旨在观察中医”从咽论治“联合西药治疗IgA肾病的临床疗效。研究指出,中医”从咽论治“联合西药可以明显改善IgA肾病患者的临床症状,尤其对于血尿的防治效果更好,其治疗效果与肾小球、肾小管间质损伤程度密切相关。该文发表在2013年第09期《中国中西医结合肾病杂志》上。 53例临床分型为”反复肉眼血尿型“或”尿检异常型“的IgA肾病患者,随机分为治

2014JSN临床实践指南——IgA肾病发布

2016年4月,日本肾脏病学会(JSN)发布了IgA肾病指南2014年版,旨在为日本IgA肾病的临床管理提供循证指导,文章主要包括3大部分内容,分别为:概念,诊断,流行病学。指南针对这些内容个提出14个临床问题,并针对这些临床问题提出推荐意见。全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积分下载)